Motif Bio (LON:MTFB) Rating Reiterated by Peel Hunt

Motif Bio (LON:MTFB)‘s stock had its “under review” rating reissued by equities researchers at Peel Hunt in a note issued to investors on Wednesday, May 1st, ThisIsMoney.Co.Uk reports.

LON:MTFB traded up GBX 0.15 ($0.00) during mid-day trading on Wednesday, hitting GBX 7.75 ($0.10). 3,586,981 shares of the company’s stock were exchanged, compared to its average volume of 400,302. The firm has a market capitalization of $26.54 million and a P/E ratio of -1.08. Motif Bio has a one year low of GBX 4.75 ($0.06) and a one year high of GBX 44.90 ($0.59).

About Motif Bio

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

See Also: How Investors Use a Balance Sheet

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.